Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07161830 · ClinicalTrials.gov registry record · NA
Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers
A NA study of Diabetic Foot Ulcer, sponsored by Omeza.
- Recruiting
- Registry status
- NA
- Development phase
- 130
- Enrollment target
- 3
- Study locations
NCT07161830: Recruiting NA study of Diabetic Foot Ulcer, sponsored by Omeza.
NCT07161830 is a NA study of Diabetic Foot Ulcer that is actively recruiting participants, run by Omeza. The registered enrollment target is 130 participants, below the 253-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (49% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07161830, a NA study of Diabetic Foot Ulcer, is actively recruiting participants, sponsored by Omeza.
- RECRUITING
- Registry status
- NA
- Development phase
- 130 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study aims to compare two treatment approaches for diabetic foot ulcers (DFUs): the standard of care (SOC) alone versus SOC combined with OCM. Researchers will evaluate whether adding OCM increases the likelihood of ulcers healing completely by the end of the trial period.
Primary Outcome
The primary endpoint will be the percentage of target ulcers that achieve complete wound closure within 12 weeks.
Conditions Studied
Interventions
- OTHER Standard of Care
- DEVICE Omeza® Complete Matrix
Study Locations (3)
Louisiana
- MedCentris of Denham Springs - Denham Springs
- MedCentris of Leesville - Leesville
Mississippi
- MedCentris of Southaven - Southaven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2025-12-04 |
| Est. Completion | 2027-03-30 |
| Phase | NA |
What NCT07161830 shows while recruiting
NCT07161830 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 253-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (49% lower).
The record links to 1 condition, with Diabetic Foot Ulcer appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT07161830 reports a single indexed study location in Louisiana, Mississippi.
Frequently Asked Questions
What is clinical trial NCT07161830 about?
NCT07161830 is a clinical study titled "Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers". This study aims to compare two treatment approaches for diabetic foot ulcers (DFUs): the standard of care (SOC) alone versus SOC combined with OCM. Researchers will evaluate whether adding OCM increases the likelihood of ulcers healing completely by the end of the trial period.
What is the current status of trial NCT07161830?
This trial is currently recruiting. It is a NA study. The enrollment target is 130 participants. The study started on 2025-12-04. Estimated completion is 2027-03-30.
What conditions does trial NCT07161830 study?
This clinical trial studies the following conditions: Diabetic Foot Ulcer.
What interventions are being tested in trial NCT07161830?
The interventions under investigation include: Standard of Care (OTHER), Omeza® Complete Matrix (DEVICE).
Who is sponsoring clinical trial NCT07161830?
This trial is sponsored by Omeza, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07161830 being conducted?
This trial has 3 study locations across Louisiana, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Foot Ulcer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07161830's enrollment target sits among peer trials
130 30th of 67 higher than 38 of 67 other Diabetic Foot Ulcer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Foot Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility and Effectiveness of a Remote Monitoring Program for the Treatment of Diabetic Foot Ulcers
RECRUITING · NA
-
Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating DFU and SanoGraft® in Treating VLU to SOC
RECRUITING · NA
-
A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.
RECRUITING · NA
-
Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs
RECRUITING · NA
-
Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone
RECRUITING · NA
-
Exercise Enhances Wound Healing in Patients With Diabetic Foot Ulcers
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI